(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

https://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

https://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network!. Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Seagen and Genmab: Breakthrough Cervical Cancer Trial Outcome

  • September 04th, 2023
  • 564 views

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) have reported a significant breakthrough in the Phase 3 innovaTV 301 global trial for recurrent or metastatic cervical cancer. Patients treated with TIVDAK (tisotumab vedotin-tftv) showed an improvement in overall survival (OS) compared to those receiving chemotherapy alone. An Independent Data Monitoring Committee found that OS exceeded the pre-specified efficacy threshold during interim analysis.

Additionally, key secondary endpoints, including progression-free survival and objective response rate, displayed statistically significant results. The safety profile of TIVDAK in the trial remained consistent with known information, with no new safety concerns.

On Friday, $SGEN closed at $207.91, gaining $1.84 (+0.89%), while $GMAB closed at $38.38, up $0.09 (+0.24%).

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Tags

Social Shares

Post Your Comments

Want To Find Some News?

Recent Posts

News By Industries

Tags